Ebola treatment for infected or exposed patients
Part of Infections clinical trials.
This trial provides an experimental antibody treatment called ansuvimab to people who have Ebola or have been recently exposed to it. The goal is to help their bodies fight the virus and prevent illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a lab-confirmed Ebola infection or have had a recent high-risk exposure to Ebola.
- You must be able to prove who you are.
- You must be willing to give consent, either yourself or through a legal representative.
- You must not have any medical condition that would make this treatment unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides an experimental antibody treatment called REGN-EB3 to people infected with Ebola virus. It aims to treat the infection and potentially improve recovery, and is available through special access in areas with Ebola outbreaks.
This trial tests a new medicine to prevent Ebola after you have been exposed. If you had close contact with someone who has Ebola in the last 5 days, this study could help you stay healthy.
This study looks at whether giving an Ebola treatment (Inmazeb) before the Ebola vaccine (Ervebo) changes the vaccine's effect on healthy people. It helps understand the best timing for these treatments.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This study tests a new Ebola vaccine to see if it is safe and how well it works. Healthy volunteers receive the vaccine and are monitored for side effects and immune response.
This study tests vaccines that may protect people who have been exposed to Bundibugyo virus, a rare but serious disease. If you qualify, you would receive a vaccine and be monitored to see how well it works.
Hear when a new Ebola Virus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.